Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

(2020) Simone Ragusa et al.   JOURNAL OF CLINICAL INVESTIGATION

Artificial intelligence in cancer therapy

(2020) Dean Ho   SCIENCE

Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors

(2020) Yukun Huang et al.   Nature Communications

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents

(2020) Paola Ciciola et al.   Journal of Clinical Medicine

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

(2020) Vicky Makker et al.   JOURNAL OF CLINICAL ONCOLOGY

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

(2020) David A. Braun et al.   NATURE MEDICINE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

(2020) Shaochuan Liu et al.   Cell Death & Disease

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma

(2020) Antonella Argentiero et al.   Journal of Clinical Medicine

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

(2020) Lorenzo Galluzzi et al.   Nature Reviews Clinical Oncology

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial

(2020) Chunyan Lan et al.   JOURNAL OF CLINICAL ONCOLOGY

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

(2020) Robert J. Motzer et al.   NATURE MEDICINE

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vessel co-option in cancer

(2019) Elizabeth A. Kuczynski et al.   Nature Reviews Clinical Oncology

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

The Intersection between Tumor Angiogenesis and Immune Suppression

(2019) Osama E. Rahma et al.   CLINICAL CANCER RESEARCH

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

(2019) Jason K. Sicklick et al.   NATURE MEDICINE

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Tumor Vascular CD99 Inhibits Tumor Growth

(2019) Elisabeth J. M. Huijbers et al.   Frontiers in Immunology

Activation of human vascular endothelium in melanoma metastases induces ICAM ‐1 and E‐selectin expression and results in increased infiltration with effector lymphocytes

(2019) Carsten Weishaupt et al.   EXPERIMENTAL DERMATOLOGY

Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC

(2019) Kohei Shigeta et al.   HEPATOLOGY

CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models

(2019) Huizhong Li et al.   JOURNAL OF IMMUNOTHERAPY

Tumors vs. Chronic Wounds: An Immune Cell's Perspective

(2019) Yichao Hua et al.   Frontiers in Immunology

The tumor vasculature an attractive CAR T cell target in solid tumors

(2019) Parvin Akbari et al.   ANGIOGENESIS

Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

(2019) Dhanya K. Nambiar et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

(2019) Mariangela Di Tacchio et al.   Cancer Immunology Research

Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules

(2018) Bo He et al.   JOURNAL OF PATHOLOGY

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

(2018) David F. McDermott et al.   NATURE MEDICINE

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy

(2018) Pieter-Jan van Dam et al.   SEMINARS IN CANCER BIOLOGY

The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer

(2018) Rindert Missiaen et al.   SEMINARS IN CANCER BIOLOGY

Combinations of Bevacizumab With Cancer Immunotherapy

(2018) Daniel S. Chen et al.   CANCER JOURNAL

The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy

(2018) Diana Klein   Frontiers in Oncology

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Cancer immunoediting and resistance to T cell-based immunotherapy

(2018) Jake S. O’Donnell et al.   Nature Reviews Clinical Oncology

Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents

(2017) Amalia Vartanian et al.   MELANOMA RESEARCH

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model

(2017) Paola Bocca et al.   OncoImmunology

Human umbilical vein endothelial cells promote the inhibitory activation of CD4+CD25+Foxp3+ regulatory T cells via PD-L1

(2016) Wei-Jun Chen et al.   ATHEROSCLEROSIS

Transition from inflammation to proliferation: a critical step during wound healing

(2016) Ning Xu Landén et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

(2016) Victoria L Bridgeman et al.   JOURNAL OF PATHOLOGY

Optimization of drug combinations using Feedback System Control

(2016) Patrycja Nowak-Sliwinska et al.   Nature Protocols

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer

(2016) S Chouaib et al.   ONCOGENE

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

(2016) Madelon Q. Wentink et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

(2015) Andrea Weiss et al.   ANGIOGENESIS

Galectin expression in cancer diagnosis and prognosis: A systematic review

(2015) Victor L. Thijssen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Vaccination approach to anti-angiogenic treatment of cancer

(2015) Madelon Q. Wentink et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

(2015) Aurelie Guislain et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment

(2015) Thomas F. Gajewski   SEMINARS IN ONCOLOGY

Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy

(2015) Andrea Weiss et al.   Scientific Reports

Intratumoral LIGHT Restores Pericyte Contractile Properties and Vessel Integrity

(2015) Anna Johansson-Percival et al.   Cell Reports

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma

(2015) X.-D. Liu et al.   Cancer Immunology Research

Robo4 vaccines induce antibodies that retard tumor growth

(2014) Xiaodong Zhuang et al.   ANGIOGENESIS

CAR T Cells for Solid Tumors

(2014) Sunitha Kakarla et al.   CANCER JOURNAL

Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature

(2014) John G. Facciponte et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

(2014) Khalid Bajou et al.   NATURE MEDICINE

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo

(2013) S. Yasuda et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

(2013) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

(2013) Gabriela Bindea et al.   IMMUNITY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy

(2013) Ritika Jaini et al.   INTERNATIONAL JOURNAL OF CANCER

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Scarless fetal skin wound healing update

(2012) David D. Lo et al.   BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

(2012) N G Gavalas et al.   BRITISH JOURNAL OF CANCER

Targeting Galectin-1 Overcomes Breast Cancer-Associated Immunosuppression and Prevents Metastatic Disease

(2012) T. Dalotto-Moreno et al.   CANCER RESEARCH

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

The histological growth pattern of colorectal cancer liver metastases has prognostic value

(2012) Gert G. Van den Eynden et al.   CLINICAL & EXPERIMENTAL METASTASIS

Wound Repair and Regeneration

(2012) J.M. Reinke et al.   EUROPEAN SURGICAL RESEARCH

Targeting TNF-  to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

(2012) A. Calcinotto et al.   JOURNAL OF IMMUNOLOGY

Neutrophil and endothelial adhesive function during human fetal ontogeny

(2012) C. Nussbaum et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Enhancement of T-cell-Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer

(2011) R. P. M. Dings et al.   CLINICAL CANCER RESEARCH

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

(2011) Daniel T. Fisher et al.   JOURNAL OF CLINICAL INVESTIGATION

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 Mediates the Transmigration of Regulatory T Cells across Human Hepatic Sinusoidal Endothelium

(2011) Shishir Shetty et al.   JOURNAL OF IMMUNOLOGY

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

(2011) M. Manzoni et al.   ONCOLOGY

Vascular Endothelial Expression of Indoleamine 2,3-Dioxygenase 1 Forms a Positive Gradient towards the Feto-Maternal Interface

(2011) Astrid Blaschitz et al.   PLoS One

Signalling pathways in vasculogenic mimicry

(2010) Yvette W.J. Paulis et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Vaccination against the extra domain-B of fibronectin as a novel tumor therapy

(2010) Elisabeth J. M. Huijbers et al.   FASEB JOURNAL

Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion

(2010) Xiaoyuan Huang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients

(2010) Olivier Adotevi et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Scarless Fetal Wound Healing: A Basic Science Review

(2010) Barrett J. Larson et al.   PLASTIC AND RECONSTRUCTIVE SURGERY

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

(2008) Juliana Hamzah et al.   NATURE

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY

Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking

(2007) Lucy V. Norling et al.   FASEB JOURNAL

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE